Last edition
News about "OCREVUS"
The US Food and Drug Administration reviews concerns over Ocrevus, as safety and efficacy questions emerge for its use in primary progressive multiple sclerosis patients.
Ocrevus | 16/04/2026 | By News Bureau
Roche's Fenebrutinib Matches Ocrevus in Slowing Disability Progression in PPMS Phase III Trial
Phase III FENtrepid study shows oral BTK inhibitor fenebrutinib achieved non-inferiority to Ocrevus in primary progressive multiple sclerosis, reducing disability progression risk by 12 percent with consistent subgroup benefit.
Ocrevus | 10/02/2026 | By News Bureau | 146
Roche reported positive late-breaking Phase III ACTRIMS data showing fenebrutinib reduced disability progression in Primary Progressive Multiple Sclerosis (PPMS), demonstrating non-inferiority to OCREVUS and reinforcing its potential as a first-in-class oral BTK inhibitor.
OCREVUS | 09/02/2026 | By News Bureau | 129
In the pivotal FENtrepid trial, Roche’s BTK inhibitor fenebrutinib demonstrated a meaningful reduction in disability progression in Primary Progressive Multiple Sclerosis (PPMS), performing at least on par with OCREVUS—the current standard and only approved treatment for PPMS.
OCREVUS | 15/11/2025 | By Dineshwori | 232
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy